Keith L. Lui, MBA

Keith Lui, MBA, joined DURECT in May 2020 and brings more than 20 years of biopharma experience in roles spanning global and U.S. strategy and marketing, market access and operations, sales, business development and analytics, public relations and investor relations, and patient advocacy. Over his career, Mr. Lui has become an expert at helping clinical-stage companies transition to full commercialization. He has made significant contributions to the strategic planning and launches of new medicines, including Imbruvica® (ibrutinib) and Zelboraf® (vemurafenib), and new indication launches for therapies such as Avastin® (bevacizumab) and Rituxan® (rituximab). Previously, Mr. Lui helped build the U.S. corporate infrastructure, commercial function, and launch strategy at Oncopeptides. Prior to that, he led early commercial strategy and launch-readiness efforts at Prothena and Versartis and led the launch of Imbruvica at Pharmacyclics. Mr. Lui also worked in multiple oncology marketing roles at Genentech and held roles in pharmaceutical sales and genomics research. He earned a Bachelor of Arts in integrative biology from the University of California at Berkeley and a Master of Business Administration with distinction from Vanderbilt University.